MARKET

EVOK

EVOK

Evoke Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.290
+0.020
+1.57%
Pre Market: 1.290 0 -0.01% 08:35 09/24 EDT
OPEN
1.280
PREV CLOSE
1.270
HIGH
1.300
LOW
1.200
VOLUME
100
TURNOVER
--
52 WEEK HIGH
5.00
52 WEEK LOW
0.9600
MARKET CAP
41.85M
P/E (TTM)
-4.0099
1D
5D
1M
3M
1Y
5Y
Evoke Pharma (NASDAQ:EVOK) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Simply Wall St. · 09/10 11:53
Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R.Ph., President and Chief Executive O...
GlobeNewswire · 09/01 12:30
Virpax Pharmaceuticals, Sesen Bio leads healthcare gainers; Qualigen Therapeutics, Sema4 among major losers
Gainers: Virpax Pharmaceuticals VRPX +96%, Sesen Bio (NASDAQ:SESN) +28%, Terns Pharmaceuticals (NASDAQ:TERN) +16%, 23andMe ME +16%, NanoVibronix (NASDAQ:NAOV) +9%. Losers: Qualigen Therapeutics QLGN -16%, Sema4 (NASDAQ:SMFR) -14%, AcelRx Pharmaceuticals (N...
Seekingalpha · 08/17 15:03
HVBT, PSTI and DPW among pre market gainers
Enlivex Therapeutics ENLV +22% to launch Phase IIb Allocetra trial for COVID-19 patients in Israel ADMA Biologics ADMA +17% on FDA approval for plasma collection facility in Maryville, TN Travere Therapeutics TVTX +17% meets primary efficacy
Seekingalpha · 08/16 12:42
24 Stocks Moving in Monday's Pre-Market Session
Gainers Enlivex Therapeutics Ltd. (NASDAQ: ENLV) shares rose 26.6% to $12.87 in pre-market trading after the company disclosed that after reviewing its earlier-reported Phase II trial data, the Israeli Ministry of Health has authorized the initiation of a ...
Benzinga · 08/16 11:20
SESN, ACY among mid-day movers
Gainers: GreenVision Acquisition (NASDAQ:GRNV) +154%. Evoke Pharma(NASDAQ:EVOK) +29%. LifeStance Health  (NASDAQ:LFST) +24%. CVD Equipment (NASDAQ:CVV) +23%. Pilgrim's Pride Corporation (NASDAQ:PPC) +21%. AbCellera Biologics (NASDAQ:ABCL) +21%. AeroCentury...
Seekingalpha · 08/13 16:43
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 08/13 16:37
What's Up With Evoke Pharma's Stock Popping Off Friday?
Evoke Pharma Inc (NASDAQ: EVOK) shares are trading higher by 23.1% at $1.38 after the company reported better-than-expected second-quarter EPS results.
Benzinga · 08/13 16:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EVOK. Analyze the recent business situations of Evoke Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EVOK stock price target is 9.00 with a high estimate of 9.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 4.98M
% Owned: 15.37%
Shares Outstanding: 32.44M
TypeInstitutionsShares
Increased
6
383.22K
New
4
205.80K
Decreased
4
179.26K
Sold Out
8
185.40K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.99%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Chairman/Co-Founder/Director
Cam Garner
Chief Executive Officer/Founder/Director
David Gonyer
Executive Vice President/Treasurer/Secretary
Matthew D'Onofrio
Other
Marilyn Carlson
Director
Todd Brady
Director
Vickie Reed
Director
Kenneth Widder
No Data
About EVOK
Evoke Pharma, Inc. (Evoke) is a specialty pharmaceutical company. Evoke operates in the development and commercialization of pharmaceutical products. Evoke is focused primarily on the development and commercialization of drugs to treat gastrointestinal( GI) disorders and diseases. Evoke is developing its product Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide offering systemic delivery by nasal spray administration.

Webull offers kinds of Evoke Pharma Inc stock information, including NASDAQ:EVOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVOK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVOK stock methods without spending real money on the virtual paper trading platform.